Date: 2020-12-15
Type of information: Nomination
Compound:
Company: Vectivbio (Switzerland)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- On December 15, 2020, VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced the appointment of Sandip Kapadia to its Board of Directors.
Mr. Kapadia has over 20 years of life science industry experience. He currently serves as Chief Financial Officer of Intercept Pharmaceuticals. Mr. Kapadia held numerous finance leadership positions at Novartis and its affiliates in the United Kingdom, Netherlands, Switzerland and the United States, most recently serving as Chief Financial Officer of Novartis’s generic division, Sandoz, in North America. He earned his B.S. in accounting from Montclair State University and an MBA from Rutgers University. Mr. Kapadia is also a U.S. Certified Public Accountant (CPA).
Financial terms:
Latest news:
Is general: Yes
